Financials
Financial year 2025
PHARMALORRAINE from Aubange, company number BE0455089059, closed financial year 2025 with a result of € 115,026 after tax. For that financial year PHARMALORRAINE recorded a gross margin of € 465,884 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € 137,524 to € 115,026. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 20, 2026.
€ 1.6 million
▲ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 115,026
▼ 16% vs 2024
Profit after tax over the fiscal year.
€ 84,905
▼ 28% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.6 million.
People and assets in 2025
3.8
▼ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 220,889
€ 58,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 4,640
▼ 45% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 407,717
▼ 9% vs 2024
€ 41,545 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 127,972
▼ 7% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 32,151
▼ 60% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 481,755 | € 445,504 | € 527,121 | € 465,884 | ▼ 12% |
| Profit after taxes | € 149,054 | € 72,239 | € 137,524 | € 115,026 | ▼ 16% |
| Equity | € 1,299,935 | € 1,372,173 | € 1,509,697 | € 1,624,723 | ▲ 8% |
| Total debts | € 578,317 | € 843,410 | € 765,636 | € 633,888 | ▼ 17% |
| Cash | € 184,147 | € 135,233 | € 118,293 | € 84,905 | ▼ 28% |
| Land & buildings | € 193,239 | € 547,397 | € 516,996 | € 473,486 | ▼ 8% |
| Retained profit | € 1,237,935 | € 1,310,173 | € 1,447,697 | € 1,562,723 | ▲ 8% |
| Dividend | € 100,000 | € 0 | € 0 | € 0 | |
| Bank debt | € 181,281 | € 492,315 | € 446,589 | € 407,717 | ▼ 9% |
| Balance sheet total | € 1,878,252 | € 2,215,583 | € 2,275,333 | € 2,258,612 | ▼ 1% |
| Employees (FTE) | 3.7 | 4.1 | 4 | 3.8 | ▼ 0.2 |
Key figures of PHARMALORRAINE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMALORRAINE?
What happened at PHARMALORRAINE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 115,026 (▼ 16% vs 2024). filed late Source: NBB ↗
- New establishment in Aubange. KBO
- Start of the company according to the CBE. KBO
In short
From € 149,054 profit in 2022 to € 115,026 profit in 2025.
Paid € 174,641 in corporate taxes since 2022.
Best year ever: 2022, with € 149,054 profit.
On average € 122,600 of value added per employee in 2025.
A new publication or filing at PHARMALORRAINE? We notify you, reason included.
Follow PHARMALORRAINEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of ExpansionPharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMALORRAINEBehind PHARMALORRAINE are Joëlle Denis and Olivier Groffy. The shares are held by ExpansionPharma (98%). It owns 99.9% of DELTA SUD PHARMA itself.
Directors
According to the 2025 annual accounts
Joëlle Denis
Managing director
Also active at: AKT - CCI Luxembourg Belge, Pharmacie Forthomme, Pharmacie BODARD, PHARMADEFI, PHARMACIE HITTELET, L.O.J'M, ExpansionPharma, DYNAMIC PHARMA +1 more
Olivier Groffy
Managing director
Also active at: Pharmacie Forthomme, Pharmacie BODARD, PHARMADEFI, PHARMACIE HITTELET, L.O.J'M, ExpansionPharma, DYNAMIC PHARMA, delta SUD PHARMA
Shareholders
98%
Participations
99.9%
Establishments
Establishment units
Physical locations of this company
Avenue de la Gare - AUBANGE 3
6790 Aubange
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0455.089.059
- VAT number
- BE 0455.089.059
- Registered office
- Avenue de la Gare - AUBANGE 3, 6790 Aubange
- Names & denominations
- PHARMALORRAINE
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 April 1995
- Peppol
- Active · Active since 26 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers
Verhuur van woningen, exclusief sociale woningen
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen